Pharma Pulse 9/12/24: AI Will Force a Transformation of Tech Infrastructure, Obesity Drug Market to be Worth $200 Billion by 2031 & more
Report: Obesity Drug Market Estimated to be Worth $200 Billion by 2031
In the current obesity drug market, GLP-1 agonists manufactured by Novo Nordisk and Eli Lilly have garnered the majority of the attention. Currently, the two companies hold a combined 68% of sales from weight-loss drugs, however, new entrants are set to challenge their market share, according to a report by Morningstar. Biopharma companies such as Roche, Amgen, Pfizer, and AstraZeneca are currently developing obesity drugs of their own, with 16 new drugs expected by 2029, according to the report. Analysts added that this could result in an additional $70 billion in the GLP-1 market by 2031.
From Opioids to Cannabis: The Impact of Cannabis Rescheduling on Pharmacy Revenue Streams
The DEA will have a hearing in December 2024 regarding the potential reclassification of cannabis to Schedule III, which could significantly impact the regulatory environment for pharmacies and their involvement in the cannabis market.
AI Will Force a Transformation of Tech Infrastructure
Corporate technology executives need to ensure their cloud and private infrastructure is ready to handle their data needs to come.
FDA Grants Clearance for Immunis’ Phase II Sarcopenic Obesity Trial
Immunis, Inc. was recently granted permission by the FDA to proceed with its Phase II clinical trial testing its investigational secretome (IMMUNA) in reversing sarcopenic obesity. The news comes shortly after Immunis completed secretome-treatment of its third patient cohort in a Phase I/IIa clinical trial for age-related muscle atrophy (sarcopenia).
Are you including enough folic acid in your diet?
During National Folic Acid Awareness Week, learn about the benefits and how much you should be consuming. fda.gov/food…
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
